Literature DB >> 7373038

Multiple myeloma: an immunologic profile. Cytotoxic and suppressive effects of the EA rosette-forming cell.

T Paglieroni, M R Mackenzie.   

Abstract

Lymphoid cells bearing receptors for human IgG anti-Rh antibody but not otherwise identifiable as T or B cells were isolated from the peripheral blood of human multiple myeloma patients. These cells do not demonstrate surface immunoglobulin, do not secrete immunoglobulin in culture after stimulation with pokeweed mitogen, and do not possess receptors for the third component of complement. They do not form rosettes with sheep erythrocytes, and do not respond to known T cell mitogens. These cells are not phagocytic and do not possess demonstrable nonspecific esterase. Thus, they must be considered at present, members of the "third population" lymphoid cells. These cells are active in the cytotoxic response by myeloma peripheral blood lymphocytes to myeloma plasma cells accounting for approximately 60% of such activity. They are also responsible for part of the suppression of pokeweed mitogen-stimulated immunoglobulin production, and at equivalent suppressor to target cell ratios are more active than immunoregulatory monocytes. Thus, these cells play an important, not previously widely appreciated role in the pathophysiology of the human myeloma patient.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7373038

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Antigen stimulated IgM secretion by circulating B lymphocytes in patients with benign and malignant IgG gammopathy. Relationship to stage of disease.

Authors:  S Pollack; R Katz; I Tatarsky; A Carter
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

2.  Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells.

Authors:  M Massaia; U Dianzani; P Pioppo; E Sibilla; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

3.  Cell-bound immunoglobulin on peripheral blood mononuclear cells of patients with myeloma.

Authors:  M A King; J V Wells
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

4.  T-cell imbalances in patients with multiple myeloma: an analysis by monoclonal antibodies.

Authors:  C D Platsoucas; H J Hansen; J R Redman; S Berenson; B J Lee; B D Clarkson
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

5.  Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies.

Authors:  M Massaia; U Dianzani; A Bianchi; A Camponi; M Boccadoro; A Pileri
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

6.  The mode of action of splenic suppressor cells in murine plasmacytoma.

Authors:  Y Chen; P Heller
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

7.  Membrane phenotype and functional behaviour of T lymphocytes in multiple myeloma: correlation with clinical stages of the disease.

Authors:  F Lauria; R Foa; M Cavo; M Gobbi; D Raspadori; M C Giubellino; P L Tazzari; S Tura
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

8.  Use of immunologic markers in obscure hematologic disease.

Authors:  C H Miller; S Mann; J Hamersley; F J Glassy; L F O'Grady
Journal:  West J Med       Date:  1983-10

9.  Regulation of immunoglobulin synthesis by monocytes in multiple myeloma and benign monoclonal gammopathy.

Authors:  A Takeshita
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

10.  Production of interleukin 2 in multiple myeloma.

Authors:  T Commes; B Klein; M Jourdan; R Bataille
Journal:  Clin Exp Immunol       Date:  1986-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.